Expression of Constitutive Fusion of Ubiquitin to PCNA Restores the Level of Immunoglobulin A/T Mutations During Somatic Hypermutation in the Ramos Cell Line.
A/T mutation pathway
PCNA monoubiquitination
Ramos B cell line
USP1 inhibition
immunoglobulin somatic hypermutation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
02
2022
accepted:
11
03
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
20
4
2022
Statut:
epublish
Résumé
Somatic hypermutation (SHM) of immunoglobulin (Ig) genes is a B cell specific process required for the generation of specific and high affinity antibodies during the maturation of the immune response against foreign antigens. This process depends on the activity of both activation-induced cytidine deaminase (AID) and several DNA repair factors. AID-dependent SHM creates the full spectrum of mutations in Ig variable (V) regions equally distributed at G/C and A/T bases. In most mammalian cells, deamination of deoxycytidine into uracil during S phase induces targeted G/C mutagenesis using either direct replication of uracils or TLS mediated bypass, however only the machinery of activated B lymphocytes can generate A/T mutagenesis around AID-created uracils. The molecular mechanism behind the latter remains incompletely understood to date. However, the lack of a cellular model that reproduces both G/C and A/T mutation spectra constitutes the major hurdle to elucidating it. The few available B cell lines used thus far to study Ig SHM indeed undergo mainly G/C mutations, that make them inappropriate or of limited use. In this report, we show that in the Ramos cell line that undergoes constitutive G/C-biased SHM in culture, the low rate of A/T mutations is due to an imbalance in the ubiquitination/deubiquitination reaction of PCNA, with the deubiquitination reaction being predominant. The inhibition of the deubiquitinase complex USP1-UAF1 or the expression of constitutive fusion of ubiquitin to PCNA provides the missing clue required for DNA polymerase η recruitment and thereafter the introduction of A/T base pair (bp) mutations during the process of IgV gene diversification. This study reports the establishment of the first modified human B cell line that recapitulates the mechanism of SHM of Ig genes
Identifiants
pubmed: 35432321
doi: 10.3389/fimmu.2022.871766
pmc: PMC9010874
doi:
Substances chimiques
Immunoglobulin A
0
Proliferating Cell Nuclear Antigen
0
Ubiquitin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
871766Informations de copyright
Copyright © 2022 Lerner, Bonte, Le Guillou, Mohammad, Kasraian, Sarasin, Despras and Aoufouchi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Exp Med. 2005 Apr 18;201(8):1191-6
pubmed: 15824086
DNA Repair (Amst). 2010 Jul 1;9(7):777-84
pubmed: 20452294
J Immunol. 1999 Mar 15;162(6):3437-47
pubmed: 10092799
Nucleic Acids Res. 2007;35(17):5819-30
pubmed: 17720710
PLoS One. 2012;7(12):e51748
pubmed: 23284758
Nat Commun. 2019 Jun 28;10(1):2849
pubmed: 31253762
DNA Repair (Amst). 2015 Aug;32:24-32
pubmed: 25956862
Nature. 2021 Dec;600(7888):324-328
pubmed: 34819670
Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):621-9
pubmed: 19008189
Cell Cycle. 2004 Aug;3(8):1011-3
pubmed: 15280666
Nat Immunol. 2001 Jun;2(6):537-41
pubmed: 11376341
Int Immunol. 2001 Sep;13(9):1175-84
pubmed: 11526098
mBio. 2011 Oct 11;2(5):
pubmed: 21990614
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Aug 1;1179:122853
pubmed: 34325309
Mol Cell. 2011 Aug 19;43(4):649-62
pubmed: 21855803
Genes Dev. 2001 Jan 15;15(2):158-72
pubmed: 11157773
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16248-53
pubmed: 18854411
Mol Cell Biol. 2014 Jun;34(12):2176-87
pubmed: 24710273
Cell. 2011 Sep 16;146(6):918-30
pubmed: 21925315
Front Immunol. 2019 Mar 12;10:438
pubmed: 30915081
Immunity. 1998 Dec;9(6):859-69
pubmed: 9881976
J Exp Med. 2007 Jan 22;204(1):17-23
pubmed: 17190840
Nucleic Acids Res. 2013 Aug;41(15):7356-69
pubmed: 23761444
Mol Immunol. 2007 Apr;44(10):2659-66
pubmed: 17240451
Nature. 2002 Oct 31;419(6910):944-7
pubmed: 12410315
J Exp Med. 2007 Aug 6;204(8):1989-98
pubmed: 17664295
Nature. 2021 Dec;600(7888):329-333
pubmed: 34819671
Nat Commun. 2016 Nov 04;7:13326
pubmed: 27811911
DNA Repair (Amst). 2017 Jun;54:46-54
pubmed: 28458162
Mol Med. 1995 Jul;1(5):495-505
pubmed: 8529116
Neuro Oncol. 2016 Jan;18(1):37-47
pubmed: 26032834
Annu Rev Biochem. 2007;76:1-22
pubmed: 17328676
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7976-81
pubmed: 11427727
FEBS Lett. 2011 Sep 16;585(18):2780-5
pubmed: 21640107
Nucleic Acids Res. 2010 Aug;38(15):5047-58
pubmed: 20385585
Cold Spring Harb Perspect Biol. 2013 Apr 01;5(4):a012633
pubmed: 23545421
Mol Cell. 2005 Feb 4;17(3):331-9
pubmed: 15694335
J Virol. 2001 Nov;75(21):10488-92
pubmed: 11581418
J Vis Exp. 2011 Nov 01;(57):e3573
pubmed: 22083360
Chem Rev. 2006 Feb;106(2):302-23
pubmed: 16464007
Immunity. 1997 Jan;6(1):35-46
pubmed: 9052835
Nat Immunol. 2002 Sep;3(9):815-21
pubmed: 12145648
Cell. 2007 May 18;129(4):665-79
pubmed: 17512402